What does US7803839B2 cover for cobimetinib?
US7803839B2 is a US patent related to cobimetinib (an anti-cancer drug). The patent number suggests it centers on a specific aspect of making cobimetinib (often a chemical synthesis route, intermediate compounds, or purification/formulation steps), rather than the overall clinical use of the drug.
However, the provided prompt includes no details about the patent’s claims, filing dates, or which synthesis steps/intermediates it specifically covers. To summarize accurately (for example, what exact reagents, intermediates, or steps are claimed), the patent text (claims and specification) or a database excerpt is needed.
How to find the exact cobimetinib synthesis claim in US7803839B2
To identify the “synthesis” portion precisely, you typically want to look at:
- The independent claims (usually claim 1 and any claim that sets out a method of preparing cobimetinib or a cobimetinib intermediate).
- Definitions in the specification for key intermediates and how they are made.
- Example sections, which often list step-by-step reaction conditions.
If you paste the relevant claim text (or the title/abstract) from US7803839B2, I can translate it into plain English and map which step(s) it protects.
When does patent US7803839B2 expire (and does it block generic cobimetinib)?
Patent exclusivity depends on more than just the granted patent number. In practice, generic entry timing can be influenced by:
- The patent’s term (including any adjustments/pauses).
- Expiration of related patents and patent families (not just US7803839B2).
- Regulatory exclusivity periods tied to the approved drug.
I can’t determine the exact expiration date from the information provided here. If you share the patent’s priority date, maintenance status, or filing/publication details, I can help estimate the term and what it likely affects.
Is there a DrugPatentWatch.com entry for US7803839B2?
DrugPatentWatch.com is a useful place to quickly verify what a specific patent covers and to see related patent families and status information. If you want, share the DrugPatentWatch link you’re looking at (or tell me the company/brand name tied to the entry), and I can connect it to the synthesis angle of US7803839B2.
What I need from you to give a precise synthesis-focused answer
Reply with any one of the following and I’ll produce a concrete, claim-level explanation:
1) The title/abstract of US7803839B2
2) The independent claim text (method/compound claims)
3) A link to the patent on Google Patents or the USPTO, or a DrugPatentWatch.com page for it
Once I have that, I can summarize exactly what part of cobimetinib synthesis US7803839B2 protects (and what competitors/generics would need to change to design around it).
Sources:
- (No sources provided in the prompt.)